Vascular Biogenics Ltd (VBLT)

[staccani]

I think we have already reached the primary endpoint. Below my reasoning.

Assuming BEV behaves as in historical data (and BEV historical rates are quite solid with more than 600 patients and also let us not forget that this trial enrolled patients also with big tumors so we should not see an improvement vs historical in BEV cohort) depending on when the 189th event is reached , we should have the following estimated survival rates in the two arms, at the cut off:

1) September ca 20% BEV vs 30% VB111
2) October ca 18% BEV vs 32% VB111
3) November ca 16% BEV vs 34% VB111
4) December ca 15% BEV vs 35% VB111
5) January ca 12% BEV vs 38% VB111

This means that since not announced yet, we should have met already the primary endpoint of significant survival improvement vs BEV arm